The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1638
November 29, 2021
View Complete Issue         Table of Contents 2019 
Olanzapine/Samidorphan (Lybalvi) for Schizophrenia and Bipolar Disorder
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Olanzapine/Samidorphan (Lybalvi) for Schizophrenia and Bipolar Disorder
November 29, 2021 (Issue: 1638)
The FDA has approved Lybalvi (Alkermes), a fixed-dose combination of the second-generation antipsychotic olanzapine (Zyprexa, and generics) and samidorphan, a new opioid antagonist, for treatment of adults with schizophrenia or with manic or...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Olanzapine/Samidorphan (Lybalvi) for Schizophrenia and Bipolar Disorder
Article code: 1638d
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.